Pharmaceutical

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Feb 2, 2024 - 18:00
AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL
AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Read the original article

Tags:

Previous Article

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

Next Article

As England’s virus hospitalisations surge flu vaccines evolve

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: AstraZeneca sues to stop Medicare drug price negotiation program

STAT+: AstraZeneca sues to stop Medicare drug price neg...

Aug 25, 2023

STAT+: Federal advisory group rejects proposal to make medical device tracking easier

STAT+: Federal advisory group rejects proposal to make ...

Jun 14, 2023

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Oncoinvent’s Radspherin has FDA fast-track status for o...

Jun 26, 2024